APO RESEARCH · REPORT
Insulin Glargine
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Product & engineering
Understand the product.
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Selected research
Market Structure
Global Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
Read the full market overview
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
This report provides an overview of the global Insulin Glargine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Insulin Glargine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Insulin Glargine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Insulin Glargine market size, projected growth trends, production technologies, key applications, and end-use industries.
Insulin Glargine Segment by Company
Sanofi-Aventis
Ganlee
Biocon
Insulin Glargine Segment by Type
Single Dose Vial
Pre-filled Syringe
Insulin Glargine Segment by Application
Treat Type2 Diabetes
Treat Type1 Diabetes
Insulin Glargine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Insulin Glargine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Single Dose Vial
- Pre-filled Syringe
Applications
- Treat Type2 Diabetes
- Treat Type1 Diabetes
Companies covered
- Sanofi-Aventis
- Ganlee
- Biocon
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Insulin Glargine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Insulin Glargine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Insulin Glargine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Insulin Glargine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Insulin Glargine Market Dynamics
- 2.1 Insulin Glargine Industry Trends
- 2.2 Insulin Glargine Industry Drivers
- 2.3 Insulin Glargine Industry Opportunities and Challenges
- 2.4 Insulin Glargine Industry Restraints
3 Insulin Glargine Market by Manufacturers
- 3.1 Global Insulin Glargine Revenue by Manufacturers (2021-2026)
- 3.2 Global Insulin Glargine Sales by Manufacturers (2021-2026)
- 3.3 Global Insulin Glargine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Insulin Glargine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Insulin Glargine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Insulin Glargine Manufacturers, Product Type & Application
- 3.7 Global Insulin Glargine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Insulin Glargine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Insulin Glargine Players Market Share by Revenue in 2025
- 3.8.3 2025 Insulin Glargine Tier 1, Tier 2, and Tier 3
4 Insulin Glargine Market by Type
- 4.1 Insulin Glargine Type Introduction
- 4.1.1 Single Dose Vial
- 4.1.2 Pre-filled Syringe
- 4.2 Global Insulin Glargine Sales by Type
- 4.2.1 Global Insulin Glargine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Insulin Glargine Sales by Type (2021-2032)
- 4.2.3 Global Insulin Glargine Sales Market Share by Type (2021-2032)
- 4.3 Global Insulin Glargine Revenue by Type
- 4.3.1 Global Insulin Glargine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Insulin Glargine Revenue by Type (2021-2032)
- 4.3.3 Global Insulin Glargine Revenue Market Share by Type (2021-2032)
5 Insulin Glargine Market by Application
- 5.1 Insulin Glargine Application Introduction
- 5.1.1 Treat Type2 Diabetes
- 5.1.2 Treat Type1 Diabetes
- 5.2 Global Insulin Glargine Sales by Application
- 5.2.1 Global Insulin Glargine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Insulin Glargine Sales by Application (2021-2032)
- 5.2.3 Global Insulin Glargine Sales Market Share by Application (2021-2032)
- 5.3 Global Insulin Glargine Revenue by Application
- 5.3.1 Global Insulin Glargine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Insulin Glargine Revenue by Application (2021-2032)
- 5.3.3 Global Insulin Glargine Revenue Market Share by Application (2021-2032)
6 Global Insulin Glargine Sales by Region
- 6.1 Global Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Insulin Glargine Sales by Region (2021-2032)
- 6.2.1 Global Insulin Glargine Sales by Region (2021-2026)
- 6.2.2 Global Insulin Glargine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Insulin Glargine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Insulin Glargine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Insulin Glargine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Insulin Glargine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Insulin Glargine Revenue by Region
- 7.1 Global Insulin Glargine Revenue by Region
- 7.1.1 Global Insulin Glargine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Insulin Glargine Revenue by Region (2021-2026)
- 7.1.3 Global Insulin Glargine Revenue by Region (2027-2032)
- 7.1.4 Global Insulin Glargine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Insulin Glargine Revenue (2021-2032)
- 7.2.2 North America Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Insulin Glargine Revenue (2021-2032)
- 7.3.2 Europe Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Insulin Glargine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Insulin Glargine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi-Aventis
- 8.1.1 Sanofi-Aventis Company Information
- 8.1.2 Sanofi-Aventis Business Overview
- 8.1.3 Sanofi-Aventis Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi-Aventis Insulin Glargine Product Portfolio
- 8.1.5 Sanofi-Aventis Recent Developments
- 8.2 Ganlee
- 8.2.1 Ganlee Company Information
- 8.2.2 Ganlee Business Overview
- 8.2.3 Ganlee Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Ganlee Insulin Glargine Product Portfolio
- 8.2.5 Ganlee Recent Developments
- 8.3 Biocon
- 8.3.1 Biocon Company Information
- 8.3.2 Biocon Business Overview
- 8.3.3 Biocon Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Biocon Insulin Glargine Product Portfolio
- 8.3.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Insulin Glargine Value Chain Analysis
- 9.1.1 Insulin Glargine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Insulin Glargine Production Mode & Process
- 9.2 Insulin Glargine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Insulin Glargine Distributors
- 9.2.3 Insulin Glargine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst